The latest price target for Plus Therapeutics (NASDAQ:PSTV) was reported by D. Boral Capital on December 11, 2025. The analyst firm set a price target for $5.00 expecting PSTV to rise to within 12 months (a possible 712.88% upside). 22 analyst firms have reported ratings in the last year.

The latest analyst rating for Plus Therapeutics (NASDAQ:PSTV) was provided by D. Boral Capital, and Plus Therapeutics maintained their buy rating.

The last upgrade for Plus Therapeutics Inc happened on September 3, 2025 when D. Boral Capital raised their price target to $5. D. Boral Capital previously had a hold for Plus Therapeutics Inc.

The last downgrade for Plus Therapeutics Inc happened on May 5, 2025 when D. Boral Capital changed their price target from N/A to N/A for Plus Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Plus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Plus Therapeutics was filed on December 11, 2025 so you should expect the next rating to be made available sometime around December 11, 2026.

While ratings are subjective and will change, the latest Plus Therapeutics (PSTV) rating was a maintained with a price target of $5.00 to $5.00. The current price Plus Therapeutics (PSTV) is trading at is $0.62, which is out of the analyst’s predicted range.